maverix-oncology
(2)
Steven Everett
Steven Everett is a biotechnology executive and cancer scientist who founded MaveriX Oncology in Palo Alto, California, where he serves as President and CEO. With a background rooted in more than two decades of cancer research at the University of Oxford, University of Dundee and UCSF, he has built his career around a single idea: making cancer drugs that switch on only inside tumors. At MaveriX he is developing conditionally activated small-molecule therapeutics that exploit hydroxylase biology in the tumor immune microenvironment, aiming to hit cancer hard while sparing healthy tissue.
Kimberly Nearing
Kimberly Nearing is the Chief Business Officer of MaveriX Oncology, a Palo Alto biotech building tumor-selective small molecule drug conjugates. She is a Venture Partner at BVCF (Bioveda China Fund) and spent over a decade as Managing Director and Head of Life Sciences at the Hong Kong-based Cedrus Group, building bridges for capital and deals between the U.S., Europe, and Greater China. With early operating years at Amgen, Merck, and IBM Healthcare and a master's from Harvard, she pairs deep biotech operating experience with the relationships that move money across the Pacific.